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Effects of Curcumin Supplementation on Inflammation and
Metabolic Profiles in Hemodialysis Patients: A Systematic
Review and Meta-Analysis of Randomized Controlled Trials
To the Editor:
Curcumin (diferuloylmethane) is the active component in turmeric (Curcuma longa) and the one responsible for its yellow color and its anti-inflammatory/
antioxidant activity.1 Curcumin is believed to have
anti-inflammatory effects by downregulating the
expression of the Nuclear factor kB (NF-kB) which
results in significant reduction of major inflammatory
cytokines and adhesion molecules, for example, proinflammatory interleukins.2,3 Hemodialysis (HD) patients
are at high risk of malnutrition and cardiovascular complications due to oxidative stress and inflammation. It is
estimated that 40%–60% of HD patients have
inflammation.4
Anti-inflammatory benefits of curcumin supplementation in HD patients have been examined in several studies. In 2014, Pakfetrat et al5 published the first randomized
controlled trial (RCT) comparing curcumin supplementation versus placebo (PBO) in patients with chronic kidney
disease (CKD) on HD, which showed significant reduction in inflammation represented by reduction in the highsensitivity C-reactive protein (hs-CRP) level among the
curcumin group. Since then, many RCTs have compared
curcumin supplementation versus PBO with conflicting
findings.6–9 Therefore, we conducted this systematic
review and meta-analysis to evaluate the impact of curcumin supplementation on inflammation and metabolic profiles among HD patients.
All RCTs that compared curcumin supplementation
with PBO in patients with CKD on HD and reported
the difference in inflammation represented by hs-CRP
were eligible for inclusion. We excluded observational
studies or studies that included patients with CKD
who are not on HD. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) Statement guidelines to select the final studies.10 Two investigators (A.B. and O.S.) independently
performed the search and shortlisted the studies for
final review. Discrepancies were resolved by a third
reviewer (K.S.).
The primary outcome of our study was the antiinflammatory effect of curcumin represented by the
change in the hs-CRP level. The secondary outcomes

were the lipid profile including total cholesterol (TC),
triglycerides (TG), low-density lipoprotein (LDL), and
high-density lipoprotein (HDL) in addition to fasting
blood sugar (FBS).
We performed a meta-analysis of the included studies
using comprehensive meta-analysis (Biostat, Englewood,
CO). The median and interquartile ranges were converted to mean and SD where applicable.11 The
random-effects model was used to calculate the standardized mean difference (SMD) with 95% confidence
intervals (CIs). A P value ,0.05 was considered statistically significant. Where the mean and SD of the change
from baseline to end point were not reported in the original studies, an imputed value for the correlation coefficient (r) was used to calculate them.12 We performed a
sensitivity analysis using r of 0.4, 0.5, and 0.6 for our
meta-analyses, and the results did not significantly
change, indicating that our analyses were robust to this
assumption.12 We used r of 0.5 in our meta-analysis.13
The heterogeneity was evaluated using the I2 statistic as
defined by the Cochrane handbook for systematic
reviews. The I2 value of $50% was considered significant heterogeneity for all outcomes.14
To confirm the robustness of our results, sensitivity
analysis for hs-CRP using leave-one-out meta-analysis
was performed to see whether it had a significant
influence on the meta-analysis result (ie, jack-knife sensitivity analysis). The Jadad composite scale was used
to assess the methodological quality of the clinical trials based on randomization, blinding, and withdrawals.15 The scale ranged from 0 to 5 points.15
Studies with a total score of $3 were considered to
have a low risk of bias. Two authors (O.S. and A.B.)
independently assessed each study for bias. Discrepancies were resolved by a third reviewer (K.S.).
A total of 7 RCTs5–9,16,17 with 413 patients with CKD
on HD (204 received curcumin supplementation and
209 received PBO) were included. All the included
RCTs were published between January 2014 and June
2021 and included hemodialysis patients. Based on
country of origin, 5 studies originated from Iran and
2 studies from Brazil. Regarding the design of studies,
all of them were RCTs. The follow-up duration ranged
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from 8 to 12 weeks. Although 6 studies5,8,9,16,17 provided curcumin supplementation in capsule forms,
one study 6 provided the curcumin supplementation
in a form of juice. All the included RCTs scored $3
according to the Jadad composite scale.
Across all the 7 studies, our meta-analysis showed a
significant reduction in hs-CRP levels among HD
patients compared with placebo (SMD 20.41; 95% CI
20.61 to 20.21; P ,0.001; I2 5 0%; Figure 1A). The
results remained consistent on leave-one-out sensitivity
analysis. Three studies7, 9, 17 reported the effect of curcumin supplementation on glycemic profile. There was
no significant effect of curcumin on FBG (SMD 20.30;
95% CI 20.60 to 0.007; P 5 0.056; I2 5 0%; Figure 1B).
Three studies6,9,17 reported the effect of curcumin
supplementation on lipid profile, which included total
cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)
levels. There was no significant effect of curcumin
intake on TG (SMD 20.17; 95% CI 20.51 to 0.16; P
5 0.31; I2 5 0%; Figure 2A), TC (SMD 20.25; 95% CI
20.62 to 0.11; P 5 0.17; I2 5 12.7%; Figure 1A), LDL

Letters to the Editor

(SMD 20.28; 95% CI 20.69 to 0.13; P 5 0.175; I2 5
27.6%; Figure 2C), or HDL (SMD 0.21; 95% CI 20.13
to 0.55; P 5 0.23; I2 5 0%; Figure 2D).
We thoroughly investigated the impact of curcumin
supplementation on inflammation and metabolic profile
among patients with CKD on HD in this meta-analysis
of RCTs. We observed a significant improvement in the
inflammation (ie, hs-CRP levels) with curcumin supplementation in HD patients. However, there was no significant change in the metabolic profile (lipid profile
and glycemic profile).
Our results regarding the effects of curcumin on
the inflammation and metabolic profiles were in line
with the trial by Vafadar-Afshar et al,9 which
showed significant reduction in the proinflammatory markers such as increased levels of hs-CRP
and adhesion molecules such as: intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion
molecule-1 (VCAM-1) among the HD patients who
received curcumin supplementation compared with
the placebo group (P ,0.05). However, curcumin
supplementation did not significantly improve the

FIGURE 1. Forest plots comparing between curcumin and placebo regarding (A) hs-CRP and (B) fasting blood sugar.
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FIGURE 2. Forest plots comparing between curcumin and placebo regarding (A) triglycerides, (B) total cholesterol, (C)
LDL, and (D) HDL.

metabolic profiles (FBS and lipid profile) (P .0.05).9
The anti-inflammatory effect of curcumin in HD
patients may be explained by its ability to inhibit
oxidative stress and reactive oxygen species generation in addition to what mentioned above.18
There are certain limitations to our study that
should be acknowledged. First, despite pooling 7
www.americantherapeutics.com

RCTs, the number of patients included in this
meta-analysis was relatively small (413 patients).
Therefore, further large-scale RCTs are necessary to
confirm our findings. Second, the included RCTs in
our analysis were conducted in 2 countries (Brazil
and Iran), which may affect generalizability to other
populations. Third, although the random-effects
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model was used in our analysis, there was mild to
moderate heterogeneity noted in the measurement of
TC and LDL. This might be driven by differences in
patient characteristics, inconsistent follow-up duration, the variations in the curcumin dosage, and formulas used in the included studies. Fourth, the lack
of patient-level data did not allow to control for the
presence of other confounding factors. Finally, we
could not assess publication bias because of the limited number of included studies. Despite the limitations, to the best of our knowledge, this is the first
meta-analysis of RCTs to compare the effect of curcumin versus placebo on inflammation and metabolic profiles in HD patients.
In conclusion, our meta-analysis demonstrated a significant improvement in inflammatory biomarkers
among HD patients without substantial effects on lipid
and glycemic profiles. Curcumin supplementation
may have an anti-inflammatory effect in this selected
patient population. However, further trials with larger
sample size and longer duration of follow-up are
needed to validate our findings.
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